Background: The aim of this national population-based cohort study was to compare rates of reintervention after surgical myotomy versus sequential pneumatic dilatation for the primary management of oesophageal achalasia.
Introduction
Oesophageal achalasia is the most common primarily motility disorder of the oesophageal body and lower oesophageal sphincter. Its incidence varies from 0⋅3 to 1⋅63 per 100 000 people, and increases with age to 17 per 100 000 among patients aged 80 years or older 1 -4 . Common symptoms associated with achalasia include chest pain, odynophagia, dysphagia, regurgitation and weight loss 5 , with treatment aimed primarily at improving oesophageal drainage and control of symptoms 6 . For at least 30 years the two most commonly used therapies were endoscopic pneumatic dilatation and Heller myotomy, and a lively debate has ensued about which of these should be the preferred treatment; botulinum toxin is used less commonly as a bridge therapy or in high-risk patients. Interestingly, Lopushinsky and Urbach 7 reported that nearly 60 per cent of patients with achalasia remained untreated in Canada (Ontario) during their study period (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) and, among patients who received any treatment, 80 per cent underwent pneumatic dilatation as first treatment and 20 per cent myotomy (either open or laparoscopic).
Previous RCTs 8, 9 failed to demonstrate any consistent difference in long-term outcome after surgical myotomy compared with pneumatic dilatation as first-line treatment for achalasia. The most recently conducted European multicentre RCT 10, 11 comparing surgical myotomy with sequential pneumatic dilatation did not demonstrate any significant differences in rates of therapeutic success between the treatment groups at 2 or 5 years. In contrast, other smaller randomized trials 12, 13 , and a recent population-based study from the USA 14 , suggested that surgical myotomy is associated with fewer reinterventions than pneumatic dilatation.
The objectives of the present study were to compare rates of reintervention and oesophageal perforation after the two most common treatment approaches, surgical myotomy and sequential pneumatic dilatation, for the primary management of oesophageal achalasia in a national population-based English cohort.
Methods
This study was based on a nationwide English populationbased cohort of patients aged over 17 years who were diagnosed with achalasia between 1 January 2002 and 31 March 2012. Data were derived from the Hospital Episode Statistics (HES) database 15 . This is a record-based system that collects patient-level data from all National Health Service (NHS) hospitals in England. It captures all patients treated in public sector hospitals and a minority treated in privately funded institutions. Patients are given a unique HES identifier that allows all of their hospital admissions to be tracked throughout the entire data set. HES data are a well validated data set and have been used in several previous publications concerning upper gastrointestinal conditions 16 -19 . Permissions for the comparison of anonymized administrative data were obtained from the National Information Governance Board for Health and Social Care in England.
Patients with achalasia were identified using the oesophageal achalasia diagnostic code K220 from ICD-10. Patients were tracked through HES using their unique identifier to ascertain interventions performed. All patients diagnosed with oesophageal cancer were excluded from the analysis to avoid the inclusion of those with pseudoachalasia. Interventions were classified into three groups and identified using OPCS-4 codes. The duration of follow-up was measured from the date of first intervention until the end of the study period (31 March 2012), or date of death as defined by the Office of National Statistics database. All diagnostic and procedural codes were checked centrally and locally as an additional verification step.
Treatment groups
The period of investigation was from 2002 to 2012; however, the HES data set extends back to 1997. Therefore, it was possible to exclude patients with any preceding intervention within 5 years of the start of this study, to ensure that the primary treatment used to classify the patients most likely represented the primary treatment for oesophageal achalasia. Patients were divided into one of two treatment groups based on the primary treatment within the study interval: surgical myotomy (OPCS codes G091, G092), with or without an additional antireflux component, or sequential pneumatic dilatation (OPCS codes G152, G153, G155, G182, G183, G185, G443, G446). A third intervention, primary botulinum toxin, was used in some patients (OPCS codes G434, G436, X851). However, in the present study only outcomes from surgical myotomy and sequential pneumatic dilatation were compared. As this was a national population-based cohort study, in the absence of a strict protocol for pneumatic dilatation, sequential pneumatic dilatation in this study referred to a primary series of up to three dilatations within 2 months; any further intervention was considered a reintervention.
Outcomes
The primary outcome was the need for reintervention. Secondary outcomes included time to reintervention (defined using OPCS codes described above for primary intervention), total number of reinterventions, frequency of reinterventions per year, type of reintervention, 30-and 90-day mortality (after primary intervention), oesophageal perforation (ICD-10 code K223) and oesophagectomy (OPCS codes G011-9, G021-9, G031-9). Potential confounders available in HES that were studied were age, sex and Charlson co-morbidity index (CCI). Pre-existing medical co-morbidity was defined using separate components of the Royal College of Surgeons modified Charlson Index 20 .
Statistical analysis
Unmatched and matched comparisons were made of surgical myotomy versus sequential pneumatic dilatation, based on the primary treatment. Reintervention, 30-and 90-day mortality, oesophageal perforation, oesophagectomy, categorized CCI score and sex were analysed using the χ 2 test. Total number of reinterventions, frequency of reinterventions per year, follow-up and age are presented as mean(s.d.), and were analysed using the independent-samples t test. Time to reintervention was analysed by means of Kaplan-Meier curves and the log rank test. Cox multivariable regression analysis was performed to identify patient and treatment factors associated with reintervention and 30-day mortality following primary treatment. The co-variables included in this regression model were age (less than 40 (reference), 41-60, 61-80, over 80 years), sex (male (reference), female), CCI (score less than 2 (reference), 2 or more) and primary intervention (surgical myotomy (reference), sequential pneumatic dilatation). An additional subset analysis was performed that specifically assessed reinterventions in both groups more than 6 months after the initial treatment, to exclude the effect of early reinterventions.
To control for potential confounders, the two treatment cohorts were matched using a propensity model. Propensity scores were calculated with a logistic regression model predicting the dependent variable of myotomy or pneumatic dilatation. Co-variables included in the model were sex (male, female), age (20 or less, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, over 80 years), CCI (categorical score 0 to 9) and length of follow-up (continuous variable in years). Patients who underwent myotomy were matched, with exact propensity scores, on a one-to-one basis with patients in the pneumatic dilatation cohort, creating two exactly matched cohorts for comparison. The comparative analysis described above was repeated with these two matched cohorts. The risk of reintervention by year was compared for the two treatment groups as part of the propensity score-matched analysis.
All statistical analyses were performed using SPSS ® version 24 (IBM, Armonk, New York, USA).
Results
Over the 11-year study interval, 14 705 patients were diagnosed with achalasia, giving an annual incidence of new diagnosis of 1337 per year. During this period, 7487 patients (50⋅9 per cent) received interventional treatment: 1742 (23⋅3 per cent) underwent primary surgical myotomy, 4534 (60⋅6 per cent) sequential pneumatic dilatation and 1211 (16⋅2 per cent) received primary botulinum toxin injection (OPCS codes G434, G436, X851). Of patients 
Values in parentheses are 95 per cent confidence intervals.
who underwent primary surgical myotomy, 1114 (63⋅9 per cent) had a concurrent antireflux procedure. The number of patients diagnosed with oesophageal achalasia increased with patient age (Fig. 1a) and the proportion of patients managed with an endoscopic or surgical intervention decreased with age (Fig. 1b) . As age increased, the proportion of patients receiving surgical myotomy decreased, with a concomitant rise in the proportion of patients receiving endoscopic therapy with botulinum toxin injection or pneumatic dilatation (Fig. 2) .
Unmatched comparison of surgical myotomy versus sequential pneumatic dilatation
Patients who had surgical myotomy were younger (mean age 44⋅8 versus 58⋅5 years; P < 0⋅001), had a greater likelihood of having a CCI score of 0 (90⋅1 versus 87⋅7 per cent; P = 0⋅003) and were more commonly men (55⋅6 versus 51⋅8 per cent; P = 0⋅020) than those who had pneumatic dilatation. Mean follow-up was 4⋅7 and 6⋅5 years for the surgical myotomy and pneumatic dilatation groups respectively. There were no significant differences between groups in the incidence of oesophageal perforation (1⋅1 versus 1⋅2 per cent respectively; P = 0⋅688). However, surgical myotomy was associated with significantly lower 30-day (0⋅1 versus 1⋅2 per cent; P < 0⋅001) and 90-day (0⋅2 versus 3⋅2 per cent; P < 0⋅001) mortality rates ( Table 1) . The proportion of patients requiring reintervention (39⋅6 versus 12⋅4 per cent; P < 0⋅001), the mean number of reinterventions (0⋅82 versus 0⋅25; P < 0⋅001) and the mean frequency of reinterventions (0⋅17 versus 0⋅06 per year; P < 0⋅001) were higher after sequential pneumatic dilatation compared with surgical myotomy. Analysis of specific reinterventions demonstrated an increase in surgical myotomy in the dilatation group compared with the myotomy group (5⋅8 versus 2⋅6 per cent; P < 0⋅001). Subset analysis of reintervention more than 6 months after the initial treatment similarly demonstrated an increase in the proportion of patients requiring reintervention in the pneumatic dilatation group (30⋅5 versus 11⋅4 per cent; P < 0⋅001).
Cox multivariable regression analysis for reintervention
Multivariable analysis demonstrated a significant reduction in reintervention as patient age increased ( Table 2) . However, sex and CCI showed no association with reintervention. Controlling for the patient factors described above, pneumatic dilatation was associated with a significant increase in reintervention compared with surgical myotomy (hazard ratio (HR) 3⋅72, 95 per cent c.i. 3⋅22 to 4⋅29; P < 0⋅001).
Multivariable analysis for 30-day mortality showed significant associations with increasing patient age (age over 80 years: HR 67⋅89, 9⋅19 to 501⋅53; P < 0⋅001) and CCI (score 2 or more: HR 2⋅57, 1⋅36 to 4⋅87; P = 0⋅004). However, there was no statistically significant association between mortality and primary treatment approach (myotomy versus dilatation) ( Table 2 ).
Matched comparison of surgical myotomy versus sequential pneumatic dilatation
Following propensity score matching, there were no statistically significant differences between the groups in age, sex, CCI or follow-up (mean 5 years). Safety of the initial treatment approach was equivalent in the two groups, with no difference in the incidence of oesophageal perforation (1⋅3 per cent for surgical myotomy and 1⋅4 per cent for pneumatic dilatation; P = 0⋅750). There was no significant difference in 30-day mortality (Table 1) . However, in this matched comparison, the proportion of patients requiring reintervention (59⋅6 versus 13⋅8 per cent; P < 0⋅001), mean number of reinterventions (1⋅36 versus 0⋅28; P < 0⋅001) and the mean frequency of reinterventions (0⋅34 versus 0⋅06 per year; P < 0⋅001) were higher following sequential pneumatic dilatation than after surgical myotomy (Fig. 3) . Analysis of specific reinterventions paralleled the unmatched comparison, with an increase in surgical myotomy in the pneumatic dilatation group compared with the surgical myotomy group. After matching, subset analysis of reintervention more than 6 months after the initial treatment similarly demonstrated an increase in the proportion of patients requiring reintervention in the pneumatic dilatation group (46⋅2 per cent versus 12⋅7 per cent in surgical myotomy group; P < 0⋅001).
Analysis of the risk of reintervention by year showed a significantly increased risk of reintervention in the pneumatic dilatation group upto 10 years after the initial treatment; after this, the number of patients in each group became very small with a low reintervention rate, limiting the power of the analysis ( Table 3) .
Discussion
This large English population-based cohort study included 14 705 patients with primary oesophageal achalasia over 11 years, and showed that half of the patients received an endoscopic or surgical intervention, paralleling previous studies 7 . As age increased, the proportion of patients receiving surgical myotomy decreased, with a concomitant increase in the proportion of patients undergoing pneumatic dilatation. After propensity score matching, the safety of both primary treatments was equivalent, with similar rates of oesophageal perforation, and 30-and 90-day mortality. Unmatched and propensity score-matched analysis suggested that surgical myotomy was associated with reduced rates of reintervention compared with sequential pneumatic dilatation. Analysis of reintervention by year demonstrated a significantly increased risk of reintervention up to 10 years following primary treatment by sequential pneumatic dilatation compared with surgical myotomy.
The limitations of this type of population-based cohort study must be acknowledged in the interpretation of the results. Risk adjustment based on the clinical symptomatic severity of achalasia or manometric achalasia subtype was not possible, as these data were not captured in the national data set used in this study. The primary outcome measure was reintervention following primary treatment. This represents a hard definable endpoint, but is limited in that it only partially describes failure of symptomatic control following achalasia treatment. Furthermore, the requirement for reintervention can be complex and multifactorial in aetiology, balancing both patient and clinical preferences. The coding of complications such as oesophageal perforation and the results generated are dependent on the reliability of the methodology and accuracy of data collection, which is a limitation shared by all national administrative databases. In addition, the quality of the intervention performed and the experience of the surgeon or endoscopist were not considered; these may represent important confounding factors affecting the results presented. However, the results of this study are reflective of the expertise and experience of practising clinicians outside of an RCT, and are more representative of the true effect sizes of the studied treatments in real clinical practice. The population-based design, with complete inclusion of all eligible patients in England, is a strength of the study. Given the low incidence of achalasia, a national data set with granularity of data to risk adjust for Eckardt score 21 and achalasia subtype 22 is unlikely to be generated. In the absence of such a data set, the present study provides a large national sample, with complete follow-up of all patients and adjustment for several known confounding factors.
The present results suggest that surgical myotomy has a low rate of reintervention (13⋅8 per cent), low mortality risk (0⋅1 and 0⋅3 per cent at 30 and 90 days respectively) and a low rate of oesophageal perforation (1⋅3 per cent), and could be considered as first-line treatment in patients with achalasia who are fit for surgical intervention. After matching, the rate of reintervention was approximately fourfold lower than that among patients receiving sequential pneumatic dilatation (59⋅6 per cent), with this difference persisting up to 10 years from primary treatment. The results of this study parallel the evidence basis for the management algorithm for achalasia published by Boeckxstaens and colleagues 23 , suggesting that surgical myotomy is the preferred treatment for management of achalasia in younger patients.
However, these results do not reproduce the most recently published medium-and long-term outcomes from the multicentre European study conducted by Boeckxstaens and co-workers 10, 11 , which suggested equivalence in clinical outcomes between surgical myotomy and sequential pneumatic dilatation. This discrepancy may be explained by differences in the quality of intervention between the present study and the RCT, in particular for pneumatic dilatation. Different protocols for dilatation have been described in the medical literature, with variation in the size of the balloon, the pressure used to disrupt the fibres (from 5 to 10 psi) and duration of dilatation (from 10 s to 1 min, or 2 min with a short interval). Within an RCT, it is possible to provide careful quality assurance measures within the structure of tight protocols followed by experienced endoscopists, to limit heterogeneity in the performance of pneumatic dilatation. Furthermore, it is important to acknowledge the difference in pneumatic dilatation protocols between the European trial and the present study. The European trial permitted up to three dilatations within 4 weeks, a second series of dilatations if symptoms recurred within or after the first 2 years, and a third series if symptoms recurred more than 2 years after the second series. Reintervention or treatment failure was considered only outside of these planned treatment series. Previous smaller RCTs 8, 12, 13 that have demonstrated increased rates of reintervention following pneumatic dilatation often considered reintervention after the initial series of two or three sequential dilatations as treatment failure. The present study has demonstrated, in national practice with a variable level of expertise of clinicians and heterogeneity in dilatation protocols, that the results of pneumatic dilatation are inferior to those reported in the RCT 10, 11 and inferior to those of surgical myotomy.
Patient age and medical co-morbidities clearly influenced the primary treatment approach, with an increase in the proportion of patients receiving pneumatic dilatation as primary treatment as age increased. Sequential pneumatic dilatation had a reintervention rate of approximately 60 per cent, and appeared to represent a viable alternative to surgical myotomy in patients considered unfit for surgery. An interesting finding was that half of patients diagnosed with oesophageal achalasia did not receive an endoscopic or surgical intervention during the study interval, and were presumably managed with medical therapy. This parallels a previous study 7 from Canada, in which nearly 60 per cent of patients with achalasia remained untreated over a 12-year interval.
Considering the safety of primary treatment, the rate of oesophageal perforation was approximately 1 per cent for both treatments. However, the clinical consequences of oesophageal perforation during these two procedures are very different. During myotomy there is the opportunity for surgical repair, often with a single suture, with no substantial alteration to the clinical course of the patient. In contrast, perforation following pneumatic dilatation requires urgent intervention by an experienced oesophageal surgeon to close the defect, with or without concurrent myotomy, and substantially changes the clinical course.
Given the rarity of oesophageal achalasia, its new characterization into three different subtypes and the multiple modalities available for primary treatment, it would seem logical in the future for these patients to be discussed in a multidisciplinary team meeting in a similar manner to patients with oesophageal cancer. Such meetings would allow gastroenterologists and surgeons to come to a combined decision regarding the best treatment approach for individual patients, taking into account age, co-morbidities, physiological reserve, symptoms and achalasia subtype. International consensus guidelines are currently being developed for the management of achalasia and should provide an evidence basis to inform such discussions. Further new interventions in the management of achalasia not examined in this study include peroral endoscopic myotomy (POEM), a promising new method for performing endoluminal myotomy 26, 25 . POEM is a technically demanding procedure and requires a high level of endoscopic skill with careful patient selection 26 , again suggesting the need for multidisciplinary team discussion of patients with oesophageal achalasia. Comparison of clinical and patient-reported outcomes of POEM compared with surgical myotomy remains an important area for future investigation.
